Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.

All technologies
 are listed as non-confidential technical summaries.

Technologies were generated by academic institutions, entrepreneurs, and corporations.

Click the Tech Search button below to have Whiteboard 2 Boardroom® staff complete a personalized search for innovations to license from our research institution partners.

The most recent innovations from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available. 

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Boron-based Polycystic Kidney Disease Therapy

This invention features novel compounds and a method of treatment to reduce cyst growth in Polycystic Kidney Disease (PKD). The compounds target a key cellular pathway involved in abnormal growth in PKD and other rapidly developing disorders, including cancer and neurological disorders. In PKD, numerous fluid-filled cysts are formed by the rapid production of tubule epithelial cells, resulting in massively enlarged kidneys and a progressive decline in renal function. There is no approved clinical therapy directed at the cellular defect responsible for PKD. This invention addresses the need for a new PKD treatment by the design, synthesis and development of novel ILK inhibitors.

Integrin-linked kinase (ILK) is a signaling molecule that bridges the communication between the extracellular matrix and cell signaling pathways through cell surface integrin. The inventors designed and synthesized specific binding compounds. These compounds target abnormal cell growth by reducing two specific kinds of signaling, both of which have been implicated in cyst growth in PKD and tumor growth in cancer. Initial drug screenings showed compounds inhibiting cell multiplication in small concentrations.


  • These inhibitors have higher efficacy, increased specificity, reduced toxicity and increased cell permeability compared to commercially available inhibitors, such as CPD-22
  • Initial drug screenings showed compounds inhibiting cell growth


  • PKD
  • Cancer
  • Neurological disorder disease
  • Ocular disease
  • Other hyperproliferative diseases with aberrant ILK activity.
  • Could also be used as novel radiosensitizers for many diseases with drug resistance
  • Or as novel materials for drug delivery and imaging tools


Additional Details


University of Kansas

Intellectual Property Protection


Interested? Request More Information